- Home
- Investors
- News / Press Releases
- Press Releases
Press Releases
Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
Tonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD at the 2017 Military Health System Research Symposium
Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
Tonix Pharmaceuticals to Present at the 2017 BIO International Convention
Tonix Pharmaceuticals Participated in the "Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets” Summit Sponsored by U.S. Department of Defense
Tonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference
Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study
